Canagliflozin Cuts Hospitalization Risk for HF in Type 2 Diabetes Patients

March 12, 2018

The CANVAS Program is the longest, largest and broadest completed CV outcomes program of any SGLT2 inhibitor to date

Canagliflozin (Invokana; Janssen) significantly decreased the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes, according to data from the CANVAS Program presented at the American College of Cardiology’s 67th Annual Scientific Session.

Leave a Reply

Your email address will not be published. Required fields are marked *